PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NTRA vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NTRA and SRPT is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

NTRA vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Natera, Inc. (NTRA) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
73.61%
-18.55%
NTRA
SRPT

Key characteristics

Sharpe Ratio

NTRA:

3.44

SRPT:

-0.15

Sortino Ratio

NTRA:

4.11

SRPT:

0.13

Omega Ratio

NTRA:

1.53

SRPT:

1.01

Calmar Ratio

NTRA:

3.35

SRPT:

-0.17

Martin Ratio

NTRA:

32.74

SRPT:

-0.38

Ulcer Index

NTRA:

4.75%

SRPT:

18.66%

Daily Std Dev

NTRA:

45.30%

SRPT:

47.89%

Max Drawdown

NTRA:

-77.74%

SRPT:

-98.17%

Current Drawdown

NTRA:

-1.51%

SRPT:

-36.18%

Fundamentals

Market Cap

NTRA:

$23.00B

SRPT:

$10.90B

EPS

NTRA:

-$1.74

SRPT:

$1.54

PEG Ratio

NTRA:

0.00

SRPT:

159.25

Total Revenue (TTM)

NTRA:

$1.22B

SRPT:

$1.24B

Gross Profit (TTM)

NTRA:

$723.52M

SRPT:

$1.05B

EBITDA (TTM)

NTRA:

-$98.44M

SRPT:

$119.07M

Returns By Period

In the year-to-date period, NTRA achieves a 10.07% return, which is significantly higher than SRPT's -6.18% return.


NTRA

YTD

10.07%

1M

3.96%

6M

72.65%

1Y

153.18%

5Y*

36.25%

10Y*

N/A

SRPT

YTD

-6.18%

1M

-9.67%

6M

-20.14%

1Y

-9.14%

5Y*

-1.29%

10Y*

24.95%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NTRA vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTRA
The Risk-Adjusted Performance Rank of NTRA is 9797
Overall Rank
The Sharpe Ratio Rank of NTRA is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of NTRA is 9797
Sortino Ratio Rank
The Omega Ratio Rank of NTRA is 9595
Omega Ratio Rank
The Calmar Ratio Rank of NTRA is 9595
Calmar Ratio Rank
The Martin Ratio Rank of NTRA is 9999
Martin Ratio Rank

SRPT
The Risk-Adjusted Performance Rank of SRPT is 3737
Overall Rank
The Sharpe Ratio Rank of SRPT is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 3636
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 3535
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 3636
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 3939
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NTRA vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Natera, Inc. (NTRA) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NTRA, currently valued at 3.44, compared to the broader market-2.000.002.004.003.44-0.15
The chart of Sortino ratio for NTRA, currently valued at 4.11, compared to the broader market-4.00-2.000.002.004.004.110.13
The chart of Omega ratio for NTRA, currently valued at 1.53, compared to the broader market0.501.001.502.001.531.01
The chart of Calmar ratio for NTRA, currently valued at 3.35, compared to the broader market0.002.004.006.003.35-0.17
The chart of Martin ratio for NTRA, currently valued at 32.74, compared to the broader market-10.000.0010.0020.0032.74-0.38
NTRA
SRPT

The current NTRA Sharpe Ratio is 3.44, which is higher than the SRPT Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of NTRA and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.006.00SeptemberOctoberNovemberDecember2025February
3.44
-0.15
NTRA
SRPT

Dividends

NTRA vs. SRPT - Dividend Comparison

Neither NTRA nor SRPT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NTRA vs. SRPT - Drawdown Comparison

The maximum NTRA drawdown since its inception was -77.74%, smaller than the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for NTRA and SRPT. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-1.51%
-36.18%
NTRA
SRPT

Volatility

NTRA vs. SRPT - Volatility Comparison

Natera, Inc. (NTRA) has a higher volatility of 13.48% compared to Sarepta Therapeutics, Inc. (SRPT) at 8.07%. This indicates that NTRA's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
13.48%
8.07%
NTRA
SRPT

Financials

NTRA vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between Natera, Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab